New Jersey’s federal courts are witnessing a notable increase in patent litigation, primarily driven by pharmaceutical companies filing claims against generic-drug manufacturers. From May 20-26, seven patent suits were filed in the District of New Jersey, significantly higher than the typical rate of one new patent suit per week. This upward trend continued with another three patent suits filed from May 26-30.
Among the cases, five were initiated by Esperion Therapeutics, aiming to prevent rivals from marketing generic versions of its cholesterol drug, Nexletol. For more details on this surge in patent litigation, visit the original article here.